TCR2 Therapeutics Inc (NASDAQ:TCRR)
| 1.60 Delayed Data As of May 26 |  -0.15 / -8.57%Today’s Change | 0.82 Today|||52-Week Range 3.88 | +60.19% Year-to-Date |
Latest TCRR News | Press Releases
No recent news for TCR2 Therapeutics Inc.
Today’s Trading
| Previous close | 1.75 |
| Today’s open | 1.72 |
| Day’s range | 1.55 - 1.72 |
| Volume | 35,002 |
| Average volume (3 months) | 484,612 |
| Market cap | $73.4M |
Data as of 3:59pm ET, 05/26/2023
Growth & Valuation
| Earnings growth (last year) | -49.39% |
| Earnings growth (this year) | +30.64% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 0.52 |
Competitors
| ---- | ||
| ---- | ||
| --Herantis Pharma Oyj | 0.00 | 0.00% |
| ABEOAbeona Therapeutics ... | -0.12 | -3.74% |
Data as of 3:59pm ET, 05/26/2023
Financials
| Next reporting date | August 9, 2023 |
| EPS forecast (this quarter) | -$0.79 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$151.8M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
